Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial
{{output}}
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy have revolutionized the treatment landscape of hormone receptor (HR)-positive advanced breast cancer. However, reliable biomarkers f... ...
